Open-Label Phase 1/2 Study of VELCADE for Injection in Patients With Light-chain (AL)-Amyloidosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT00298766

Recruitment Status : Completed

First Posted : March 3, 2006

Results First Posted : August 13, 2010

Last Update Posted : June 25, 2012

Sponsor:

Collaborator:

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Information provided by (Responsible Party):

Millennium Pharmaceuticals, Inc.

Study Description

Brief Summary:

This is a phase 1/2 open-label, dose-escalation study investigating single-agent therapy with VELCADE in patients with previously treated systemic AL-amyloidosis who require further treatment.

Condition or disease	Intervention/treatment	Phase
Amyloidosis	Drug: VELCADE	Phase 1 Phase 2

Study Design

Layout table for study information

Study Type :	Interventional (Clinical Trial)
Actual Enrollment :	70 participants
Allocation:	Non-Randomized
Intervention Model:	Single Group Assignment
Masking:	None (Open Label)
Primary Purpose:	Treatment
Official Title:	An Open-Label Phase 1/2 Study of VELCADE for Injection in Subjects With Light-Chain (AL)-Amyloidosis
Study Start Date :	June 2005
Actual Primary Completion Date :	July 2009
Actual Study Completion Date :	September 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Amyloidosis

Drug Information available for: Bortezomib

U.S. FDA Resources

Arms and Interventions

Arm	Intervention/treatment
Experimental: 1 VELCADE	Drug: VELCADE Once weekly at: 0.7, 1.0, 1.3 or 1.6 mg/m2 Or Twice-weekly at: 0.7, 1.0, or 1.3 mg/m2 Other Name: Bortezomib

Outcome Measures

Primary Outcome Measures :

Maximum Tolerated Dose [ Time Frame: 5 weeks in once weekly (QW) dose cohorts and 3 weeks in twice weekly (BIW) dose cohorts ]
Maximum Tolerated Dose (MTD) was defined as the highest dose level that has 0/1 out of 6 patients experiences Dose Limited Toxicity (DLT). MTD is defined separately for QW and BIQ dose cohorts.

DLT was defined as adverse events occurring during Cycle 1 and: (1) related to VELCADE, (2) Grade 4 thrombocytopenia or neutropenia, (3) Grade 3 or higher nonhematologic toxicity.
Subjects With Treatment Emergent Adverse Events [ Time Frame: from first study-related procedure to 30 days after last dose of study medication ]
Treatment emergent adverse events observed during outcome measure time frame
Subjects With Serious Treatment Emergent Adverse Events [ Time Frame: from first study-related procedure to 30 days after last dose of study medication ]
Serious treatment emergent adverse events observed during outcome measure time frame
Subjects Grade 3/4/5 Treatment Emergent Adverse Events [ Time Frame: from first study-related procedure to 30 days after last dose of study medication ]
Grade 3/4/5 treatment emergent adverse events observed during outcome measure time frame.

Grade is determined according to Common Terminology Criteria for Adverse Event (CTCAE) Version 3.0.
Subjects With Treatment Emergent Adverse Events Leading to Treatment Termination [ Time Frame: from first study-related procedure to 30 days after last dose of study medication ]
Treatment emergent adverse events observed during outcome measure time frame leading to treatment termination

Secondary Outcome Measures :

Best Confirmed Hematologic Responders [ Time Frame: from first dose of study medication to end of study visit ]
Hematologic response was determined by the investigator per the response criteria for immunoglobulin light chain amyloidosis by Gertz (2005). It include Complete and Partial Responders (CR+PR). CR requires serum and urine negative for a monoclonal protein by immunofixation and free light chain ratio normal. PR requires: 1. reduction in quantitative serum M-protein by 50% if baseline value is at least 0.5 g/dL, 2. if light chain is detected in the urine (with a consistent peak and >100 mg/ 24 hours), then 50% reduction is required, 3. if free light chain >10 mg/dL, reduction by 50% is required.

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information

Ages Eligible for Study:	18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Male or Female 18 y/o and older
Female patients must be practicing an effective method of birth control
Biopsy-proven AL-amyloidosis
Must have been previously treated (failed at least 1 previous treatment) and in the opinion of the physician, patient requires further treatment

Exclusion Criteria:

Hypersensitivity to boron or mannitol
Prior treatment with VELCADE
Patient requires other concomitant chemotherapy, radiotherapy or ancillary therapy considered investigational
Uncontrolled infection

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00298766

Locations

Layout table for location information

United States, California
Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute
Los Angeles, California, United States, 90049
United States, Georgia
Winship Cancer Center - Emory Clinic School of Medicine
Atlanta, Georgia, United States, 30322
United States, Massachusetts
Boston Medical Center
Boston, Massachusetts, United States, 02118
United States, New York
MSKCC
New York, New York, United States, 10017

Sponsors and Collaborators

Millennium Pharmaceuticals, Inc.

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Investigators

Layout table for investigator information

Study Director:	Medical Monitor	Millennium Pharmaceuticals, Inc.

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Reece DE, Hegenbart U, Sanchorawala V, Merlini G, Palladini G, Bladé J, Fermand JP, Hassoun H, Heffner L, Kukreti V, Vescio RA, Pei L, Enny C, Esseltine DL, van de Velde H, Cakana A, Comenzo RL. Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis. Blood. 2014 Oct 16;124(16):2498-506. doi: 10.1182/blood-2014-04-568329. Epub 2014 Sep 8.

Reece DE, Hegenbart U, Sanchorawala V, Merlini G, Palladini G, Bladé J, Fermand JP, Hassoun H, Heffner L, Vescio RA, Liu K, Enny C, Esseltine DL, van de Velde H, Cakana A, Comenzo RL. Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study. Blood. 2011 Jul 28;118(4):865-73. doi: 10.1182/blood-2011-02-334227. Epub 2011 May 11.

Reece DE, Sanchorawala V, Hegenbart U, Merlini G, Palladini G, Fermand JP, Vescio RA, Liu X, Elsayed YA, Cakana A, Comenzo RL; VELCADE CAN2007 Study Group. Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study. Blood. 2009 Aug 20;114(8):1489-97. doi: 10.1182/blood-2009-02-203398. Epub 2009 Jun 4.

Layout table for additonal information

Responsible Party:	Millennium Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier:	NCT00298766
Other Study ID Numbers:	26866138-CAN-2007
First Posted:	March 3, 2006 Key Record Dates
Results First Posted:	August 13, 2010
Last Update Posted:	June 25, 2012
Last Verified:	June 2012

Additional relevant MeSH terms:

Layout table for MeSH terms

Amyloidosis Proteostasis Deficiencies Metabolic Diseases Bortezomib Antineoplastic Agents

To Top